Multidisciplinary Research to Accelerate Hepatitis B Cure in Persons Living with HIV and HBV (MRA-HBV)
Contract Overview
Solicitation details, issuing organization, response deadlines, documents, and interested companies for this government contract opportunity.
AI Contract Overview
The National Institute of Allergy and Infectious Diseases (NIAID) is seeking applications to support multidisciplinary research aimed at accelerating a cure for Hepatitis B in persons living with both HIV and Hepatitis B Virus (HBV). The research program focuses on understanding the mechanisms behind disease persistence and pathogenesis, identifying and developing clinically relevant biomarkers, discovering and validating new drug targets related to either the host or virus, and creating non-invasive diagnostic tools. This initiative encourages studies that utilize existing clinical data and sample repositories from past cohort studies, with each award supporting an observational cohort led by multidisciplinary teams. This contract opportunity is forecasted under the authority of the Public Health Service Act and relevant federal regulations. It is part of a larger NIH effort to promote innovative research that could lead to improved outcomes for individuals co-infected with HIV and HBV. The point of contact for further information is Dr. Josh Radke at NIAID, and full details are available through the grants.gov portal. The solicitation aims to bring together diverse expertise and leverage existing resources to enhance understanding and treatment options in this area significantly.
General Info
Agency
NAICS
Place of Performance
Not specifiedSet-Aside
Documents
(0)AI Contract Breakdown
Uniform Contract FormatNo contract breakdown available.
Cannot generate Contract Breakdown because no documents were found from this contract's source.
Timeline
Organization & Contact Information
Full Description
The National Institute of Allergy and Infectious Diseases (NIAID) seeks to advance its mission by soliciting applications to support Multidisciplinary Research to Accelerate Hepatitis B Cure in Persons Living with HIV (PLWH) and Hepatitis B Virus (HBV). This program will focus on: elucidating mechanisms of persistence and pathogenesis; discovering and developing clinically relevant biomarkers; discovering and/or validating host and/or new viral drug targets; and developing non-invasive diagnostics. Each MRA-HBV award will support an observational cohort paired with a multi-disciplinary teams focused on research that leverages samples from existing clinical data and sample repositories from previous cohort studies. Grant authorities that allow NIAID to forecast this opportunity are as follows: Sections 301 and 405 of the Public Health Service Act as amended (42 USC 241 and 284) and under Federal Regulations 42 CFR Part 52 and 2 CFR Part 200.
